Cellectis (CLLS) Income towards Parent Company (2015 - 2026)
Cellectis (CLLS) posted quarterly Income towards Parent Company of -$0.18 for Q1 2026, little changed year-over-year from -$0.18 in Q1 2025, and up 30.77% quarter-over-quarter from -$0.26 in Q4 2025.
Cellectis (CLLS) Income towards Parent Company (2015 - 2026) Analysis & Trends
Cellectis' Income towards Parent Company history runs 12 years deep, the most recent figure standing at -$0.18 for Q1 2026.
- In Q1 2026, Income towards Parent Company changed 0.0% year-over-year to -$0.18; the TTM figure through Mar 2026 stood at -$23.1 million (up 45.41% YoY), while the FY2025 annual figure was -$0.67, up 100.0% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$0.18, up from -$0.26 in the prior quarter.
- The five-year high for Income towards Parent Company was $5.9 million in Q4 2024, with the low at -$41.8 million in Q4 2023.
- The 5-year median for Income towards Parent Company is -$18.9 million (2022), against an average of -$15.7 million.
- The sharpest annual moves came in 2022 and 2024: Income towards Parent Company tumbled 168.88% in 2022, then jumped 118.76% in 2024.
- Cellectis' Income towards Parent Company stood at -$26.8 million in 2022, then plunged by 55.86% to -$41.8 million in 2023, then surged by 114.17% to $5.9 million in 2024, then sank by 100.0% to -$0.26 in 2025, then soared by 30.77% to -$0.18 in 2026.
- Business Quant data shows CLLS's Income towards Parent Company at -$0.18 in Q1 2026, -$0.26 in Q4 2025, and $589000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.18 |
| Dec 31, 2025 | -0.26 |
| Sep 30, 2025 | 589,000.00 |
| Jun 30, 2025 | -23.74 Mn |
| Mar 31, 2025 | -0.18 |
| Dec 31, 2024 | 5.92 Mn |
| Sep 30, 2024 | -23.06 Mn |
| Jun 30, 2024 | -25.27 Mn |
| Mar 31, 2024 | 5.64 Mn |
| Dec 31, 2023 | -41.80 Mn |
| Sep 30, 2023 | -17.48 Mn |
| Jun 30, 2023 | -11.71 Mn |
| Mar 31, 2023 | -30.07 Mn |
| Dec 31, 2022 | -26.82 Mn |
| Sep 30, 2022 | -28.47 Mn |
| Jun 30, 2022 | -18.95 Mn |
| Mar 31, 2022 | -31.91 Mn |
| Dec 31, 2021 | -25.00 Mn |
| Sep 30, 2021 | -37.41 Mn |
| Jun 30, 2021 | -39.92 Mn |